These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32598582)

  • 21. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating pulmonary hypertension in pediatrics.
    Lador F; Sekarski N; Beghetti M
    Expert Opin Pharmacother; 2015 Apr; 16(5):711-26. PubMed ID: 25665593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.
    Hay BR; Pugh ME; Robbins IM; Hemnes AR
    Chest; 2016 Mar; 149(3):660-6. PubMed ID: 26378379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside.
    Mazzola M; Madonna R; Badagliacca R; Caterina R
    Vascul Pharmacol; 2022 Aug; 145():107022. PubMed ID: 35738494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pulmonary arterial hypertension: changing approaches to management].
    Sidorenko BA; Preobrazhenskiĭ DV; Batyraliev TA; Belenkov IuN
    Kardiologiia; 2011; 51(1):100-8. PubMed ID: 21626809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.
    Badlam JB; Bull TM
    Ther Adv Chronic Dis; 2017 Feb; 8(2-3):47-64. PubMed ID: 28348727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence and Discontinuation of Disease-Specific Therapies for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Qadus S; Naser AY; Ofori-Asenso R; Ademi Z; Al Awawdeh S; Liew D
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):19-33. PubMed ID: 36434365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
    Badiani B; Messori A
    Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease.
    Nakanishi N; ;
    Allergol Int; 2011 Dec; 60(4):419-24. PubMed ID: 22015568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of pulmonary arterial hypertension].
    Montani D; Sitbon O; Jaïs X; Cabrol S; Simonneau G; Humbert M
    Presse Med; 2005 Nov; 34(19 Pt 2):1445-55. PubMed ID: 16301976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.